4911386 said its normalized net income for the second half was 2 fen per share, a decrease of 69.9% from 6 fen per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 13.3 million yuan, a decline of 60.5% from 33.7 million yuan in the year-earlier period.

Total revenue climbed 10.8% on an annual basis to 340.7 million yuan from 307.5 million yuan, and total operating expenses grew 27.1% from the prior-year period to 327.2 million yuan from 257.3 million yuan.

Reported net income declined 52.6% on an annual basis to 18.4 million yuan, or 2 fen per share, from 38.9 million yuan, or 6 fen per share.

For the year, the company's normalized net income totaled 9 fen per share, compared with the S&P Capital IQ consensus normalized EPS estimate of 16 fen.

EPS declined 23.8% from 12 fen in the prior year.

Normalized net income was 63.4 million yuan, a decrease of 11.9% from 71.9 million yuan in the prior year.

Full-year total revenue grew 15.5% on an annual basis to 688.0 million yuan from 595.6 million yuan, and total operating expenses increased 22.9% year over year to 597.3 million yuan from 485.9 million yuan.

The company said reported net income decreased 7.1% on an annual basis to 80.5 million yuan, or 12 fen per share, in the full year, from 86.7 million yuan, or 14 fen per share.

s of April 12, US$1 was equivalent to 6.47 yuan.Zhongzhi Pharmaceutical Holdings Ltd

4911386 said its normalized net income for the second half was 2 fen per share, a decrease of 69.9% from 6 fen per share in the prior-year period.